Join Growin Stock Community!

Arbutus biopharma corporationABUS.US Overview

US StockHealthcare
(No presentation for ABUS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ABUS AI Insights

ABUS Overall Performance

ABUS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ABUS Recent Performance

0.54%

Arbutus biopharma corporation

0.05%

Avg of Sector

-0.31%

S&P500

ABUS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ABUS Key Information

ABUS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ABUS Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Price of ABUS

ABUS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ABUS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
61.36
PB Ratio
11.68
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-289.45%
Revenue Growth (YoY)
116.64%
Profit Growth (YoY)
116.64%
3-Year Revenue Growth
-55.37%
3-Year Profit Growth
-55.37%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
61.36
PB Ratio
11.68
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-289.45%
Revenue Growth (YoY)
116.64%
Profit Growth (YoY)
116.64%
3-Year Revenue Growth
-55.37%
3-Year Profit Growth
-55.37%

  • When is ABUS's latest earnings report released?

    The most recent financial report for Arbutus biopharma corporation (ABUS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ABUS's short-term business performance and financial health. For the latest updates on ABUS's earnings releases, visit this page regularly.

  • What is the operating profit of ABUS?

    According to the latest financial report, Arbutus biopharma corporation (ABUS) reported an Operating Profit of -8.39M with an Operating Margin of -1,586.2% this period, representing a growth of 60.22% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ABUS's revenue growth?

    In the latest financial report, Arbutus biopharma corporation (ABUS) announced revenue of 529K, with a Year-Over-Year growth rate of -60.49%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ABUS have?

    As of the end of the reporting period, Arbutus biopharma corporation (ABUS) had total debt of 4.61M, with a debt ratio of 0.05. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ABUS have?

    At the end of the period, Arbutus biopharma corporation (ABUS) held Total Cash and Cash Equivalents of 22.41M, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ABUS go with three margins increasing?

    In the latest report, Arbutus biopharma corporation (ABUS) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -1,586.2%%, and net margin of -1,463.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ABUS's profit trajectory and future growth potential.

  • Is ABUS's EPS continuing to grow?

    According to the past four quarterly reports, Arbutus biopharma corporation (ABUS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.04. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ABUS?

    Arbutus biopharma corporation (ABUS)'s Free Cash Flow (FCF) for the period is -5.82M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 71.95% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ABUS?

    The latest valuation data shows Arbutus biopharma corporation (ABUS) has a Price-To-Earnings (PE) ratio of -20.74 and a Price/Earnings-To-Growth (PEG) ratio of 0.07. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.